Aplastic Anemia
Furha Cossor, M-D
Furha Cossor, MD, is a board-certified oncologist and hematologist with Saint Luke's Cancer Specialists. Dr. Cossor has a special interest in multiple myeloma, leukemia, lymphoma, myelodysplastic syndrome, and myeproliferative neoplasms.
Anand B. Karnad, MD
My career since completing my fellowship training in Hematology and Medical Oncology at Boston City Hospital has been devoted to being a clinician-educator passionate about clinical trials as the best option for care. I have led Divisions of Hematology-Oncology at ETSU and at UT Health San Antonio and have played leadership roles in the Cancer Centers at both institutions. My current career focus is on hematology (blood disorders) spanning classical (or benign) hematology and all related pre-malignant and malignant disorders of the blood, bone marrow, lymph nodes, and immune system.
Ludovica Marando, MD
Dr. Marando is a Hematologist in Houston, Texas. Dr. Marando is a dedicated hematologist who is passionate about understanding the mechanisms that govern somatic clonal mosaicism within the hematopoietic stem cell compartment and the factors that govern progression into overt myeloid neoplasms. I do firmly believe that a better understanding of these mechanisms can lead to a shift in treatment paradigms: prevention of deadly hematological cancers.
Brion V. Randolph, MD
Dr. Brion Randolph is a medical oncologist and hematologist with 23 years of experience treating patients with cancer and blood disorders. His expertise encompasses both oncology and hematology, allowing him to provide comprehensive care for patients facing complex diagnoses. Dr. Randolph focuses on delivering personalized treatment plans for individuals dealing with various forms of cancer and blood-related conditions.
Julia T. Warren, MD, PhD
Julia T. Warren, MD, PhD, joined Children's Hospital of Philadelphia in fall 2022. She is a hematologist with the Division of Hematology and the Pediatric Comprehensive Bone Marrow Failure Program.
Significant clinical impact of immunosuppressive therapy termination after allogeneic haematopoietic stem cell transplantation
The clinical impact of immunosuppression termination (IST) after allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains to be fully elucidated. This study was aimed at assessing the impact of IST within 2 years after transplantation on subsequent clinical…
CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study
Despite concerns about the toxicity of allogeneic hematopoietic cell transplantation (alloHCT) in older patients, prospective data characterizing prevalence or risk stratification for geriatric morbidity such as disability or frailty are limited. We prospectively assessed the…
How I Treat: Selection of Hematopoietic Cell Donors in the Era of Post-Transplant Cyclophosphamide
Selection of a hematopoietic progenitor cell donor for allogeneic hematopoietic cell transplantation (allo HCT) is essential for treatment planning; however, the parameters that define an "optimal" donor in the modern era are not well defined. Historically, donor-recipient human…
Platelets Measured at 1 - Kelsey's Severe Aplastic Anemia Story
In January 2025, life felt full of momentum. My husband and I had just moved from Colorado to Tennessee to be closer to family. I was beginning my real estate career, we had just bought our first house, and we had our two precious daughters, just 2 years and 10 months old.
